Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funds will be used to progress the company's lead candidate MEB–1170, an analgesic drug candidate for the prevention and treatment of Opioid Use Disorder, through IND filing and Phase 1 clinical trials.
Lead Product(s): MEB-1170
Therapeutic Area: Psychiatry/Psychology Product Name: MEB-1170
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $7.1 million Upfront Cash: Undisclosed
Deal Type: Funding October 29, 2020